Per Pfizer’s interim 2-month, Phase-3 data that they submitted to the FDA on November 20, 2020, Pfizer was measuring the effectiveness of their mRNA injection from preventing COVID-19 symptoms confirmed by a positive PCR-test versus placebo (aka, not getting injected with mRNA-LNPs).
You can see from the chart below (pulled directly from Pfizer’s FDA submission) that 8 out of 17,411 participants (0.05%) in the Pfizer mRNA injected group came down with COVID-19 symptoms confirmed by a positive PCR-test within 2 months or less after their second mRNA shot, versus 162 out of 17,511 (0.93%) in the placebo group.


